Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Activation of Hepatitis B Virus (HBV) in Hepatitis B Surface Antigen (HBsAg) - Negative But Hepatitis B Core Antibody (Anti-HBc) - Positive Patients

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Yoshihide Ueda, Kyoto University
ClinicalTrials.gov Identifier:
NCT00881036
First received: April 13, 2009
Last updated: September 2, 2015
Last verified: September 2015

April 13, 2009
September 2, 2015
August 2006
July 2015   (final data collection date for primary outcome measure)
Not Provided
Not Provided
Complete list of historical versions of study NCT00881036 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
Activation of Hepatitis B Virus (HBV) in Hepatitis B Surface Antigen (HBsAg) - Negative But Hepatitis B Core Antibody (Anti-HBc) - Positive Patients
Activation of HBV Under Immunosuppression in HBsAg-negative But Anti-HBc-positive Patients With Hematological Malignancies
Individuals with resolved hepatitis B, characterized as hepatitis B surface antigen (HBsAg)-negative and hepatitis B core antibody-positive, have latent hepatitis B virus (HBV) infection in their liver tissue. Cytotoxic chemotherapy and hematopoietic stem cell transplantation sometimes trigger the reactivation of latently infected HBV, resulting in de novo hepatitis B. Although de novo hepatitis B could cause acute liver failure or chronic hepatitis, an effective management strategy for de novo hepatitis B has not been well established. Risk factors and effective management for de novo hepatitis B will be clarified.
Not Provided
Observational
Observational Model: Cohort
Time Perspective: Prospective
Not Provided
Not Provided
Probability Sample
HBsAg-negative but anti-HBc-positive patients with hematological malignancies treated at Kyoto University Hospital
Hepatitis B
Not Provided
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
33
July 2015
July 2015   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • HBsAg-negative but anti-HBc-positive

Exclusion Criteria:

  • Serum HBV DNA-negative
Both
18 Years and older   (Adult, Senior)
No
Contact information is only displayed when the study is recruiting subjects
Japan
 
NCT00881036
HBV from anti-HBc positive
No
Not Provided
Not Provided
Yoshihide Ueda, Kyoto University
Kyoto University
Not Provided
Not Provided
Kyoto University
September 2015

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP